PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.31%
Negative revenue growth while AVGO stands at 6.34%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-6.07%
Negative gross profit growth while AVGO is at 9.30%. Joel Greenblatt would examine cost competitiveness or demand decline.
-8.06%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-9.04%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-1.78%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
No Data
No Data available this quarter, please select a different quarter.
-0.79%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-1.47%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-1.44%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-0.16%
Dividend reduction while AVGO stands at 51.63%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-48.39%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-53.02%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
133.94%
10Y revenue/share CAGR under 50% of AVGO's 739.51%. Michael Burry would suspect a lasting competitive disadvantage.
38.70%
5Y revenue/share CAGR under 50% of AVGO's 407.01%. Michael Burry would suspect a significant competitive gap or product weakness.
28.08%
3Y revenue/share CAGR under 50% of AVGO's 125.80%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
498.85%
10Y OCF/share CAGR under 50% of AVGO's 28544.39%. Michael Burry would worry about a persistent underperformance in cash creation.
175.85%
Below 50% of AVGO's 478.10%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
116.94%
3Y OCF/share CAGR at 50-75% of AVGO's 210.70%. Martin Whitman would suspect weaker recent execution or product competitiveness.
9620.45%
Net income/share CAGR above 1.5x AVGO's 4089.28% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
187.69%
5Y net income/share CAGR above 1.5x AVGO's 118.26%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
83.48%
Positive short-term CAGR while AVGO is negative. John Neff would see a clear advantage in near-term profit trajectory.
25.60%
Equity/share CAGR of 25.60% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-7.65%
Negative 5Y equity/share growth while AVGO is at 381.98%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-6.64%
Negative 3Y equity/share growth while AVGO is at 213.27%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
597.21%
Dividend/share CAGR of 597.21% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
156.46%
Below 50% of AVGO's 968.63%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
102.64%
Below 50% of AVGO's 504.14%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
19.30%
AR growth well above AVGO's 10.59%. Michael Burry fears inflated revenue or higher default risk in the near future.
-3.88%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
1.79%
Asset growth well under 50% of AVGO's 43.86%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-3.87%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
21.41%
Debt shrinking faster vs. AVGO's 115.18%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
-2.75%
Our R&D shrinks while AVGO invests at 19.51%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
No Data
No Data available this quarter, please select a different quarter.